Keytruda's Pregnancy Category and Fetal Risks
Keytruda (pembrolizumab), a PD-1 inhibitor used for cancers like melanoma and lung cancer, carries significant pregnancy risks. It's classified as Pregnancy Category D by the FDA, meaning animal studies show fetal harm and human risks outweigh benefits unless no alternatives exist.[1] Clinical trials excluded pregnant women, but data from post-marketing reports and related PD-1/PD-L1 inhibitors indicate high miscarriage rates (up to 50-70% in some analyses) and fetal abnormalities like low birth weight, preterm birth, and death.[2]
Evidence from Studies and Animal Data
In monkey studies at doses similar to human levels, Keytruda caused post-implantation loss, premature delivery, and low neonatal survival; fetuses showed immune cell depletion.[1][3] Human case reports (over 20 documented) link exposure to spontaneous abortions, stillbirths, and congenital issues like skeletal malformations. No large controlled trials exist due to ethical limits, but a 2023 review of immunotherapy pregnancies found 30% fetal loss with PD-1 blockers versus 10-15% baseline.[4]
Recommendations for Patients on Keytruda
Merck advises effective contraception during treatment and for 4 months after the last dose for women of childbearing potential, due to pembrolizumab's 22-day half-life and prolonged effects.[1] Men should use condoms during treatment and 3 months post-dose. Discontinue breastfeeding during treatment and 4 months after, as it passes into milk.[1] Oncologists recommend pregnancy testing before starting and multidisciplinary consults with maternal-fetal medicine specialists.
What If Pregnancy Occurs During Treatment?
Immediate discussion with the oncologist is critical—treatment interruption may be considered, but cancer progression risks must be weighed. Limited data shows some live births without defects after first-trimester exposure, but second/third-trimester risks include placental insufficiency.[4] Registry programs like Merck's track outcomes; patients can enroll via the manufacturer hotline.
Alternatives and Timing for Family Planning
For women planning pregnancy, delay Keytruda until after delivery if possible, or explore surgery/chemo options with lower fetal risks (e.g., certain chemotherapies post-first trimester). Post-treatment wait aligns with drug clearance, but IgG antibodies may persist longer.[3] No direct reversals exist; fertility preservation (egg freezing) is advised pre-treatment.
[1]: Keytruda Prescribing Information (Merck, 2024)
[2]: FDA Label Update on Pembrolizumab Pregnancy Risks
[3]: EMA Summary of Product Characteristics for Keytruda
[4]: Journal of Clinical Oncology Review: "PD-1 Inhibitors in Pregnancy" (2023)